Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment
NCT02976896
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
43
Enrollment
OTHER
Sponsor class
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG:
Apatinib Mesylate
Sponsor
Yuhong Li